INMB

Companies
NASDAQ
Inmune Bio Inc.
Health Care
Price Chart
Overview

About INMB

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Market Cap
$173.3M
Volume
1.9M
Avg. Volume
1.8M
P/E Ratio
-3.764706
Dividend Yield
0.00%
Employees
15.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
N/A
N/A
Volatility
N/A
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for INMB.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, INMB shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$173.3M
Volume1.9M
P/E Ratio-3.76
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025

PortfolioPilot Analysis

Get AI-powered insights on how INMB fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025